With a U.S. biotech identified as One Bio, Jiangsu Hengrui Pharmaceutical Co. Ltd. has inked an out-licensing deal potentially worth $1.05 billion for its asthma and chronic sinusitis-targeting drug, SHR-1905. The latest deal gives One Bio exclusive rights to develop, produce and commercialize SHR-1905 worldwide, excluding the greater China territory.
Related Keywords
China , ,Jiangsu Hengrui Pharmaceutical Co ,One Bio ,Jiangsu Hengrui Pharmaceutical ,Jiangsu Hengrui Pharmaceutical Co Ltd ,Asthma ,Sinusitis ,Shr 1905 ,Gyroscope Therapeutics Ltd ,Tezspire ,Tezepelumab ,Chronic ,Monoclonal Antibody ,Thymic Stromal Lymphopoietin ,
comparemela.com © 2020. All Rights Reserved.